SurgiMab news
SurgiMAb is very happy to participate in person to this exciting conference that will gather together the best KOLs in the domain. After two years of remote interactions, this conference will be a great occasion to discover exciting novelties and discuss collaborations in person.
Don’t miss the talks by Hiroto Nishino 22 January 2022 • 4:15 PM and Françoise Cailler, CEO and Scientific Director of SurgiMab
Françoise Cailler, CEO and Scientific Director of SurgiMab will attend this exciting congress, where world-renowned specialists will gather together during two days to discuss the latest advances in the field of Fluorescence-Guided Surgery. Sessions will cover basic concepts, the use of NIR technology for oncology, colorectal surgery and many more exciting and innovative fields.
SurgiMab is proud to be a sponsor of this internationally acknowledged conference, that gathers together the best specialists of Fluorescence Guided Surgery.
Don’t miss the presentations by André Pèlegrin: Antibodies, favorite tools for fluorescence-guided surgery, 02/02 at 10:30 and by Ruben Meijer: Clinical translation of novel contrast agent for image guided surgery, 02/02 at 13:30.
Françoise Cailler, CEO and
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, today announces that the first US patient has been recruited into its on-going pivotal Phase 3 clinical trial evaluating its investigational imaging agent SGM-101 in patients undergoing colorectal cancer (CRC) surgery.
The randomized Phase 3 trial, designed following discussions with the FDA and other regul
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach designed to improve cancer surgery and clinical outcomes for patients, today announces that the first surgical procedure was carried out in a pivotal Phase 3 clinical trial of the Company`s lead product, SGM-101, in a patient with colorectal cancer (CRC).
SGM-101 is a tumor-specific antibody conjugated to a dye (fluorophore) that fluoresces under nearinfra-red light; it selectivel